KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Deferred Revenue: 2011-2025

Historic Current Deferred Revenue for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $485.4 million.

  • Sarepta Therapeutics' Current Deferred Revenue rose 282.24% to $485.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $485.4 million, marking a year-over-year increase of 282.24%. This contributed to the annual value of $130.3 million for FY2024, which is 158.36% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Current Deferred Revenue is $485.4 million, which was up 22.76% from $395.4 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Current Deferred Revenue high stood at $485.4 million for Q3 2025, and its period low was $22.5 million during Q3 2023.
  • Its 3-year average for Current Deferred Revenue is $145.7 million, with a median of $112.0 million in 2024.
  • In the last 5 years, Sarepta Therapeutics' Current Deferred Revenue plummeted by 74.79% in 2023 and then surged by 464.60% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Current Deferred Revenue stood at $89.2 million in 2021, then remained steady at $89.2 million in 2022, then plummeted by 43.51% to $50.4 million in 2023, then soared by 158.36% to $130.3 million in 2024, then spiked by 282.24% to $485.4 million in 2025.
  • Its Current Deferred Revenue was $485.4 million in Q3 2025, compared to $395.4 million in Q2 2025 and $44.9 million in Q1 2025.